Axsome Therapeutics (AXSM) Sets New 1-Year High at $10.89

Axsome Therapeutics Inc (NASDAQ:AXSM) shares hit a new 52-week high on Thursday . The stock traded as high as $10.89 and last traded at $10.69, with a volume of 33659 shares. The stock had previously closed at $10.42.

Several analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Axsome Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, January 14th. ValuEngine downgraded shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. HC Wainwright set a $15.00 price objective on shares of Axsome Therapeutics and gave the company a “buy” rating in a research report on Tuesday, March 5th. LADENBURG THALM/SH SH reaffirmed a “positive” rating and set a $45.00 price objective (up from $34.00) on shares of Axsome Therapeutics in a research report on Monday, January 7th. Finally, Cantor Fitzgerald began coverage on shares of Axsome Therapeutics in a research note on Thursday, November 15th. They issued an “overweight” rating and a $16.00 target price for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $24.00.

The company has a market capitalization of $302.90 million, a PE ratio of -8.64 and a beta of 3.32. The company has a debt-to-equity ratio of 6.00, a current ratio of 1.46 and a quick ratio of 1.46.



Several large investors have recently added to or reduced their stakes in the stock. Sio Capital Management LLC increased its position in shares of Axsome Therapeutics by 115.5% in the third quarter. Sio Capital Management LLC now owns 416,458 shares of the company’s stock worth $1,437,000 after purchasing an additional 223,168 shares during the period. Worth Venture Partners LLC acquired a new position in shares of Axsome Therapeutics in the third quarter worth approximately $138,000. Alethea Capital Management LLC lifted its stake in Axsome Therapeutics by 65.9% in the fourth quarter. Alethea Capital Management LLC now owns 908,429 shares of the company’s stock valued at $2,562,000 after buying an additional 360,986 shares during the period. BlackRock Inc. lifted its stake in Axsome Therapeutics by 14.6% in the fourth quarter. BlackRock Inc. now owns 64,049 shares of the company’s stock valued at $181,000 after buying an additional 8,137 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in Axsome Therapeutics in the fourth quarter valued at approximately $98,000. 12.84% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Axsome Therapeutics (AXSM) Sets New 1-Year High at $10.89” was originally posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/03/14/axsome-therapeutics-axsm-sets-new-1-year-high-at-10-89.html.

About Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.

Featured Story: What is the downside to momentum investing?

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply